Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Ipsen ADR | CABOMETYX (cabozantinib) and TECENTRIQ (atezolizumab) - (CONTACT-02) | Castration-Resistant Prostate Cancer | sNDA Filing | Data Released | Oral and intravenous | Oncology |
| Ipsen ADR | BYLVAY (odevixibat) - (BOLD) | Biliary atresia | Phase 3 | Ongoing | Oral | Gastroenterology |
| Ipsen ADR | Fidrisertib - (FALKON) | Fibrodysplasia ossificans progressiva (FOP) | Phase 2b | Data Released | Oral | Genetic Disorder |
| Ipsen ADR | LANT (IPN10200) - (LANTIC) | Upper limb spasticity, migraine and cervical dystonia | Phase 2 | Enrollment Initiation | Intranasal | Neurology |
| Ipsen ADR | Elobixibat | Nonalcoholic steatohepatitis (NASH) | Phase 2 | Oral | Gastroenterology | |
| Ipsen ADR | Elafibranor - (ELMWOOD) | Primary sclerosing cholangitis (PSC) | Phase 2 | Ongoing | Oral | Gastroenterology |
| Ironwood Pharmaceuticals Inc. | Apraglutide - (STARS) | Short Bowel Syndrome with Intestinal Failure (SBS-IF) | NDA Filing | Ongoing | Subcutaneous | Gastroenterology |
| Ironwood Pharmaceuticals Inc. | CNP-104 | Primary Biliary Cholangitis (PBC) | Phase 2 | Trial Discontinued | Intravenous | Gastroenterology |
